PRIMARY MEMBRANOUS NEPHROPATHY
Clinical trials for PRIMARY MEMBRANOUS NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEMBRANOUS NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY MEMBRANOUS NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Kidney disease drug trial halted before it began
Disease control TerminatedThis study aimed to compare a newer drug, obinutuzumab, with a standard treatment (steroids and cyclophosphamide) for people with primary membranous nephropathy, a kidney condition. The goal was to see which approach worked better at controlling the disease, caused fewer side eff…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE3 • Sponsor: The University of Queensland • Aim: Disease control
Last updated May 26, 2026 07:03 UTC
-
New hope for kidney patients: drug may stop protein leak without lifelong pills?
Disease control OngoingThis study tests a drug called zanubrutinib in people with primary membranous nephropathy, a kidney disease that causes protein to leak into urine. The goal is to see if zanubrutinib can reduce protein levels and lead to remission better than the current standard drug, tacrolimus…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE2, PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New kidney drug zuberitamab faces off against cyclosporine in Mid-Stage trial
Disease control OngoingThis study tests a new drug, zuberitamab, in 135 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The goal is to see if zuberitamab reduces protein in urine better than the standard drug cyclosporine. Participants receive either zuberitama…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 12:08 UTC
-
New hope for kidney patients: drug may beat standard therapy
Disease control OngoingThis study tests a drug called obinutuzumab against a standard treatment (tacrolimus) in 142 people with primary membranous nephropathy, a kidney disease that lets protein leak into urine. The goal is to see if obinutuzumab can put the disease into complete remission by week 104.…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 18, 2026 12:01 UTC